Nomura Asset Management Co. Ltd. Has $118.72 Million Stock Position in Boston Scientific Co. (NYSE:BSX)

Nomura Asset Management Co. Ltd. lifted its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 13.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,329,144 shares of the medical equipment provider's stock after buying an additional 155,336 shares during the period. Nomura Asset Management Co. Ltd. owned about 0.09% of Boston Scientific worth $118,719,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. TFC Financial Management Inc. lifted its position in shares of Boston Scientific by 308.8% in the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 210 shares during the period. Dunhill Financial LLC lifted its position in Boston Scientific by 86.4% in the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 152 shares during the period. Global Wealth Strategies & Associates boosted its stake in Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after buying an additional 250 shares in the last quarter. West Oak Capital LLC bought a new stake in Boston Scientific in the 4th quarter valued at $29,000. Finally, Valley National Advisers Inc. raised its stake in shares of Boston Scientific by 262.4% in the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 286 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 1,201 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the sale, the executive vice president now owns 25,443 shares of the company's stock, valued at approximately $2,704,845.33. This represents a 4.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Daniel J. Brennan sold 67,333 shares of Boston Scientific stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the transaction, the chief financial officer now directly owns 225,808 shares in the company, valued at approximately $23,764,033.92. This represents a 22.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 137,302 shares of company stock worth $14,319,269. 0.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on BSX shares. Citigroup upped their target price on shares of Boston Scientific from $107.00 to $122.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. TD Cowen upped their price objective on Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research note on Thursday, December 12th. Raymond James raised their target price on Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research report on Thursday, February 6th. Morgan Stanley boosted their price target on Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. Finally, Argus set a $130.00 price objective on Boston Scientific in a research note on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Boston Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $108.91.

Boston Scientific Trading Up 1.6 %

Boston Scientific stock traded up $1.57 during trading hours on Monday, reaching $100.93. 4,820,051 shares of the company's stock traded hands, compared to its average volume of 6,048,591. The firm has a market capitalization of $149.29 billion, a price-to-earnings ratio of 80.67, a PEG ratio of 2.79 and a beta of 0.77. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. Boston Scientific Co. has a fifty-two week low of $66.80 and a fifty-two week high of $107.17. The firm's 50 day moving average is $102.16 and its 200-day moving average is $93.18.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. On average, analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.